| 研究課題/領域番号 |
17K15044
|
|---|
| 研究機関 | 東京大学 |
|---|
研究代表者 |
Firouzi Sanaz 東京大学, 大学院新領域創成科学研究科, 客員共同研究員 (30793400)
|
|---|
| 研究期間 (年度) |
2017-04-01 – 2019-03-31
|
| キーワード | HTLV-1 / MinION sequencer / ATL / NGS technology / Molecular Diagnosis / Clonality / Genomics / Personalized Medicine |
|---|
| 研究実績の概要 |
Characterizing HTLV-1 infected cells using various genomics approaches①Clonality analysis based on provirus integration sites using NGS technology suggested possible applications of clonality in the molecular diagnosis of ATL, as well as predicting ATL development among HTLV-1-infected individuals (Firouzi et al 2017 and Farmanbar et al 2017)②Development of a new methodology for easy-to-do, rapid and cheap enough analysis of clonality using MinIon sequencer③Showing presence of a high degree of intra-tumor heterogeneity(ITH) based on mutations among ATL patients using Whole Exome Sequencing.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
Taking advantage NGS technology, bioinformatics and mathematical approaches, I have analyzed clonality based on integration sites using an appropriate pool of clinical samples and published the results in two papers(Firouzi et al 2017 and Farmanbar et al 2017).
Also, according to my proposed plan, I have devised and optimized a method which is easy-to-do, rapid and cheap enough to be performed for personalized medicine and genetic tests not only in advanced genomics labs but also in developing countries without any infrastructures. I am preparing a manuscript for reporting the results.
Moreover, I monitored ITH based mutation profiling of ATL patients. My manuscript is currently under revision.This part has the potential to be further developed in the future.
|
| 今後の研究の推進方策 |
During the 1st year, I performed preliminary experiments for methodology development with MinIon sequencer using different cell lines as control samples. I am currently finish assessing sensitivity, reproducibility, efficiency, accuracy as well as required material, time and costs of this new method by analyzing control samples with known clonality status. I am also comparing the advantage of this new method based on MinION sequencer with my previous methodology based on NGS technology. I am also preparing a methodology manuscript. Moreover, to fulfill goals according to the initially proposed research plan, I will start analyzing large sets of clinical samples collected from HTLV-1 infected individuals from the world different endemic areas of HTLV-1 by the new MinIon based method.
|
